Gains from no real PAINS: Where ‘Fair Trial Strategy’ stands in the development of multi-target ligands
Authors:
Open Access
- 4 March 2021
- journal article
- review article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 11 (11) , 3417-3432
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (31870325)
- China Pharmaceutical University (CPU2018GY12)
This publication has 115 references indexed in Scilit:
- ToxAlerts: A Web Server of Structural Alerts for Toxic Chemicals and Compounds with Potential Adverse ReactionsJournal of Chemical Information and Modeling, 2012
- The inevitable QSAR renaissanceJournal of Computer-Aided Molecular Design, 2011
- Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents—real hits or promiscuous artifacts?Current Opinion in Chemical Biology, 2011
- Apparent activity in high-throughput screening: origins of compound-dependent assay interferenceCurrent Opinion in Chemical Biology, 2010
- A Method for Identifying Small-Molecule Aggregators Using Photonic Crystal Biosensor MicroplatesSLAS Technology, 2009
- Cdc25B Dual-Specificity Phosphatase Inhibitors Identified in a High-Throughput Screen of the NIH Compound LibraryASSAY and Drug Development Technologies, 2009
- Development of a 384-Well Colorimetric Assay to Quantify Hydrogen Peroxide Generated by the Redox Cycling of Compounds in the Presence of Reducing AgentsASSAY and Drug Development Technologies, 2008
- Stoichiometry and Physical Chemistry of Promiscuous Aggregate-Based InhibitorsJournal of the American Chemical Society, 2008
- Comprehensive Mechanistic Analysis of Hits from High-Throughput and Docking Screens against β-LactamaseJournal of Medicinal Chemistry, 2008
- Screening in a spirit haunted worldDrug Discovery Today, 2006